CIK 0001479419 · Non-accelerated filer<br>Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270604595
- Phone
- 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-11 | Rosen Howard B Director | Grant or award · Stock Option (right to buy) | +3,150 | 3,150 | ||
| 2024-06-11 | Farid Marjan Director | Grant or award | +1,400 | 7,792 | ||
| 2024-06-11 | Farid Marjan Director | Grant or award · Stock Option (right to buy) | +3,150 | 3,150 | ||
| 2024-06-11 | PERRY GREGORY D Director | Grant or award | +1,400 | 10,894 | ||
| 2024-06-11 | PERRY GREGORY D Director | Grant or award · Stock Option (right to buy) | +3,150 | 3,150 | ||
| 2024-06-11 | Myers C. Daniel Director | Grant or award | +1,400 | 7,924 | ||
| 2024-06-11 | Myers C. Daniel Director | Grant or award · Stock Option (right to buy) | +3,150 | 3,150 | ||
| 2024-06-11 | KOVEN ANDREW I Director | Grant or award | +1,750 | 13,922 | ||
| 2024-06-11 | KOVEN ANDREW I Director | Grant or award · Stock Option (right to buy) | +3,900 | 3,900 | ||
| 2024-06-11 | Blumenkranz Mark S. Director | Grant or award | +1,400 | 13,091 | ||
| 2024-06-11 | Blumenkranz Mark S. Director | Grant or award · Stock Option (right to buy) | +3,150 | 3,150 | ||
| 2024-05-31 | Bazemore Todd SEE REMARKS | Sale | −2,093 | $6.09 | $13K | 87,693 |
| 2024-05-31 | Kharabi Darius CHIEF BUSINESS OFFICER | Sale | −231 | $6.09 | $1K | 64,886 |
| 2024-05-31 | Reumuth Mary CHIEF FINANCIAL OFFICER | Sale | −1,786 | $6.09 | $11K | 64,350 |
| 2024-05-31 | Brazzell Romulus K SEE REMARKS | Sale | −2,002 | $6.09 | $12K | 89,471 |
| 2024-05-31 | Iwicki Mark T CHIEF EXECUTIVE OFFICER | Sale | −7,392 | $6.09 | $45K | 278,923 |
| 2024-01-04 | Trachtenberg Eric SEE REMARKS | Grant or award | +4,600 | 69,293 | ||
| 2024-01-04 | Trachtenberg Eric SEE REMARKS | Sale | −1,227 | $6.74 | $8K | 68,066 |
| 2024-01-04 | Trachtenberg Eric SEE REMARKS | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-01-04 | Kharabi Darius CHIEF BUSINESS OFFICER | Grant or award | +4,600 | 66,502 |
Page 4 of 12 · 236 trades